



CREXONT[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
35mg/140mg · 52.5mg/210mg
70mg/280mg · 87.5mg/350mg

David,
a real person with
Parkinson's disease

CREXONT: THE LONGEST-LASTING* ORAL LEVODOPA

Explore how CREXONT lasted longer than RYTARY and immediate-release carbidopa/levodopa (IR CD/LD) in a clinical pharmacology study
*In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.

INDICATION

CREXONT[®] (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

The most common side effects that may occur with CREXONT are nausea and anxiety.


It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.

Innovation in levodopa therapy


IN A CLINICAL PHARMACOLOGY STUDY, CREXONT provided the longest-lasting oral levodopa levels*†

IN A CLINICAL PHARMACOLOGY STUDY, Levodopa levels of CREXONT lasted longer compared with RYTARY and IR CD/LD*



- IR CD/LD has been the gold standard in Parkinson's treatment since 1970s
- It works quickly but may wear off quickly, too
IR CD/LD dissolves in the stomach and may not make it to the small intestine, where it is best absorbed
- When levodopa wears off quickly, doses don't last as long. So, more frequent daily dosing may be required to achieve symptom control

That's where **CREXONT** turns innovation into duration.



CREXONT levodopa levels outlasted RYTARY and IR CD/LD*†

*In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.
 †This was a post hoc analysis of a secondary measure in the clinical pharmacology study; CREXONT vs RYTARY: P=0.010; CREXONT vs IR CD/LD: P<0.0001.
 ‡The exact site and duration of absorption is unknown.

IMPORTANT SAFETY INFORMATION (cont'd)
 You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.
 Swallow CREXONT whole. Do not chew, divide, or crush the capsules. Do not take CREXONT with alcohol.

- Tell your healthcare provider if you:
- Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
 - Experience hallucinations or abnormal thoughts and behaviors
 - Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges

- IMPORTANT SAFETY INFORMATION (cont'd)**
- Have thoughts of suicide or have attempted suicide
 - Have abnormal involuntary movements that appear or get worse during treatment
 - Have ever had a peptic ulcer or glaucoma

- Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
 - Are breastfeeding during therapy
- Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.**

CREXONT: BUILT TO LAST



CREXONT consists of a combination of immediate release granules and innovative extended-release technology



CREXONT is designed to increase levodopa levels and make them last*



To access support and resources,
scan this QR code

*In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.

IMPORTANT SAFETY INFORMATION (cont'd)

To report **SUSPECTED ADVERSE REACTIONS**, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.



CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC.
© 2025 Amneal Pharmaceuticals LLC.
Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
All rights reserved. PP-ADP-CREX-US-0018 05/2025

